A Study of IMR-687 in Adult Participants With Sickle Cell Anemia (Homozygous HbSS or Sickle-β0 Thalassemia)

NCT03401112 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Sickle Cell Disease

Interventions

DRUG: IMR-687
DRUG: Placebo

Sponsor

Cardurion Pharmaceuticals, Inc.

Collaborators

[object Object]